• 1. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 2. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 3. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 4. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 5. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Aminopyrimidines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Aminopyrimidines and derivatives

Recent Advances in the Study of 2-(Ethylamino)pyrimidine-4-carbaldehyde (CAS: 1260788-30-4) in Chemical Biology and Pharmaceutical Research

The compound 2-(Ethylamino)pyrimidine-4-carbaldehyde (CAS: 1260788-30-4) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This heterocyclic aldehyde serves as a key intermediate in the synthesis of various biologically active molecules, particularly those targeting kinase inhibitors and other therapeutic agents. Recent studies have explored its role in modulating protein-protein interactions and its potential as a scaffold for novel drug candidates.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of 2-(Ethylamino)pyrimidine-4-carbaldehyde derivatives as selective inhibitors of cyclin-dependent kinases (CDKs), which are crucial targets in cancer therapy. The research team utilized structure-activity relationship (SAR) analysis to optimize the compound's binding affinity, achieving nanomolar potency against CDK2 and CDK4. These findings highlight the compound's potential as a starting point for developing next-generation anticancer agents with improved selectivity profiles.

In parallel research, scientists have investigated the compound's utility in fragment-based drug design (FBDD). The aldehyde functionality of 2-(Ethylamino)pyrimidine-4-carbaldehyde allows for efficient conjugation with various nucleophiles, making it particularly valuable for constructing diverse chemical libraries. A recent Nature Communications paper described its use in developing covalent inhibitors targeting cysteine residues in challenging drug targets, such as KRAS mutants, which have historically been difficult to address with traditional small-molecule approaches.

The synthetic accessibility of 2-(Ethylamino)pyrimidine-4-carbaldehyde has also been improved through recent methodological advances. A 2024 publication in Organic Letters presented a novel, high-yield synthetic route utilizing microwave-assisted chemistry, reducing the reaction time from hours to minutes while maintaining excellent purity (>98%). This development significantly enhances the compound's availability for large-scale screening campaigns and structure-optimization studies.

Pharmacokinetic studies of derivatives containing the 2-(Ethylamino)pyrimidine-4-carbaldehyde scaffold have shown promising results regarding metabolic stability and membrane permeability. Research presented at the 2024 American Chemical Society National Meeting revealed that properly substituted analogs demonstrate favorable ADME (Absorption, Distribution, Metabolism, and Excretion) properties, with several candidates advancing to preclinical development stages for inflammatory and neurodegenerative disorders.

Looking forward, the unique chemical properties of 2-(Ethylamino)pyrimidine-4-carbaldehyde continue to inspire innovative applications in chemical biology. Current research directions include its incorporation into PROTAC (Proteolysis Targeting Chimera) molecules and its use in developing covalent chemical probes for target identification and validation. The compound's versatility and the growing body of research supporting its utility suggest it will remain an important tool in medicinal chemistry for years to come.

• 180869-39-0(2-(Methylamino)pyrimidine-4-carboxaldehyde)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)